Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care. 2019

Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
Department of Infectious Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.

Background: Accidental exposure to sharp instruments is an important problem for health care students. Thus, the aim of this study was to determine the rate of immunity in health care students 2 decades after national neonatal hepatitis B (HB) vaccination. Methods: All junior students attending medicine, nursing and midwifery schools were screened for anti-HBs. One dose of hepatitis B vaccine was offered to all participants who did not have antibodies to HB surface antigen (anti-HBs) of > 10 IU/L; then, they were tested for anti-HBs after a month. The participants were classified into 3 groups: postboosting nonimmune, postboosting immune, and preboosting immune. Chi square test and ANOVA were used for data analysis. Results: In the first step, 65.20% of participants did not show immunity, but after receiving a booster dose, only 6.0% remained nonimmune. The mean age of nonimmune students was significantly higher than that of students who had postboosting immune and preboosting immune status (p=0.001 and 0.002, respectively). Also, the mean injection time from last shot was higher in postboosting immune group compared to preboosting immune group (p<0.001). Also, prebooster anti-HBs level was significantly different among participants with suboptimal response and those who developed anamnestic response, indicating preserved immune memory (p=0.001). Conclusion: High anamnestic response to HBV booster dose indicates sufficient immunity to HBV in the majority of health care students. However, identifying students who cannot respond to a booster dose of vaccine seems to be necessary at the beginning of health care courses.

UI MeSH Term Description Entries

Related Publications

Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
July 2005, Vaccine,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
June 1997, American journal of infection control,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
July 1986, The Journal of infection,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
January 2010, Vaccine,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
January 2007, Vaccine,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
December 2021, The Lancet. Microbe,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
January 1995, Bulletin of the World Health Organization,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
January 1992, American journal of nephrology,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
July 1986, The New England journal of medicine,
Behzad Bijani, and Abbas Allami, and Farzaneh Jafari, and Fatemeh Hajmanoochehri, and Soroush Bijani
March 2009, International journal of clinical practice,
Copied contents to your clipboard!